Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype

Chinese Medical Journal

Volumn 127, Issue 1, 2014, Pages 102-108

  Liang, Yan ^a   Zhang, Jun Jun ^a   Liu, Dong Wei ^a   Quan, Song Xia ^a   Xing, Guo Lan ^a   Liu, Zhang Suo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cellular crescents; Cyclophosphamide; Endocapillary proliferation; IgA nephropathy; Mycophenolate mofetil; Proteinuria

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; CYCLOPHOSPHAMIDE; GLYCYRRHIZIC ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIOPSY; BLOOD PRESSURE; CAPILLARY PROLIFERATION; FEMALE; FOLLOW UP; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN A NEPHROPATHY; LUNG INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NECROSIS; PROTEINURIA; RETROSPECTIVE STUDY; URINARY TRACT INFECTION;

ADULT; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84891700678     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132396     Document Type: Article

References (37)

1. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13 519 renal biopsies. Kidney Int 2004; 66: 920-923.
2. Donadio JV, Joseph P. IgA nephropathy. N Engl J Med 2002; 347: 738-748.
3. Abe T, Kida H, Yoshimura M, Yokoyama H, Koshino Y, Tomosugi N, et al. Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol 1986; 25: 37-41.
4. Haas M. Histological subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842.
5. Ferrario F, Napodano P, Rastaldi MP, D'Amico G. Capillaritis in IgA nephropathy. Contrib Nephrol 1995; 111: 8-12.
6. D'Amico G, Napodano P, Ferrario F, Rastaldi MP, Arrigo G. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall. Kidney Int 2001; 59: 692.
7. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy: report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 1994; 8: 15-20.
8. Cai GY, Chen XM. Immunoglobulin A nephropathy in China: progress and challenges. Am J Nephrol 2009; 30: 268-273.
9. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy:clinical and histological response to methylprednisoline and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-1329.
10. Rosselli JL, Thacker SM, Karpinski JP, Petkewicz KA. Treatment of IgA nephropathy: an update. Nephrology 2011: 45: 1284-1296.
11. Zhang YX, Zhang JR, Wang ZG. Mycophenolate mofetil affects monocyte Toll-like receptor 4 signaling during mouse renal ischemia/reperfusion injury. Chin Med J 2013: 126: 1224-1229.
12. Asaba K, Tojo A, Onozato ML, Kinugasa S, Miyazaki H, Miyashita K, et al. Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts. Intern Med 2009; 48: 883-890.
13. Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T, et al. Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol 1998: 49: 1-8.
14. Welch TR, McAdams AJ, Berry A. Rapidly progressing IgA nephropathy. Am J Dis Child 1988; 142: 789-793.
15. Subías R, Botey A, Darnell A, Montoliu J, Revert L. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol 1987; 27: 1-7.
16. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986; 59: 363-378.
17. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512.
18. Roccatello D, Rossi D, Marletto F, Naretto C, Sciascia S, Baldovino S, et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol 2012; 25: 198-203.
19. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
20. Bazzi C, Rizza V, Raimondi S, Casellato D, Napodano P, D'Amico G. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression. Clin J Am Soc Nephrol 2009; 4: 929-935.
21. Maixnerova D, Bauerova L, Skibova J, Rysava R, Reiterova J, Merta M, et al. The retrospective analysis of 343 Czech patients with IgA nephropathy-one centre experience. Nephrol Dial Transplant 2012; 27: 1492-1498.
22. Huang Y, Liu Z, Huang H, Liu H, Li L. Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005; 5: 1029-1039.
23. Ren P, Han F, Chen L, Xu Y, Wang Y, Chen J. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol 2012; 36: 271-277.
24. Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18: 821-832.
25. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942.
26. Ong LM, Hooi LS, Lim TO. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-510.
27. Laskari K, Mavragani CP, Tzioufas AG. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther 2010; 12: R208.
28. Tang Z, Yang G, Yu C. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 2008; 13: 702-707.
29. Ding L, Zhao M, Zou W, Liu Y, Wang H. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13: 113-118.
30. Onishi A, Sugiyama D, Tsuji G, Nakazawa T, Kogata Y, Tsuda K, et al. Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. Mod Rheumatol 2013; 23: 89-96.
31. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849.
32. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145.
33. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812.
34. Sydney T, Anthony T, Sunny W, Joseph L, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77: 543-549.
35. Chen X, Chen P, Cai G. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy (in Chinese). Natl Med J China 2002; 82: 796-801.
36. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
37. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: apost hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 2001; 12: 2832-2837.